Phaarmasia Limited has initiated a postal ballot process to seek shareholder approval for the sale of its land and building located in Hyderabad. The company plans to sell the property for a minimum consideration of ₹25.00 crores, as part of its strategy to optimize its asset portfolio and strengthen its financial position.

Key Details of the Proposed Sale

• Property: Land and building at Plot Nos. 16A and 16B, Phase III, IDA Jeedimetla, Hyderabad, Telangana
• Buyers: Mr. Mavuluri Shyam Prasad, Mrs. Mavuluri Raga Sudha, and/or M/s MSP LAB INSTRUMENTS PRIVATE LIMITED
• Minimum Consideration: ₹25.00 crores, subject to adjustments based on valuation reports
• Expected Completion: By December 31, 2025

Postal Ballot and E-voting Process

The company has initiated a postal ballot process to seek shareholder approval for the sale. Key dates for the e-voting process are:

Phaarmasia Limited has engaged Central Depository Services Limited (CDSL) to provide e-voting facilities to its shareholders.

Rationale for the Sale

The proposed sale is aimed at optimizing the company's asset portfolio by divesting a non-core asset. The proceeds from the sale will be utilized to:

1. Strengthen the company's balance sheet
2. Meet general corporate requirements
3. Fund capital expenditure
4. Address working capital needs

Shareholder Approval and Legal Compliance

The sale requires approval through a special resolution under Section 180(1)(a) of the Companies Act, 2013, and other applicable SEBI regulations. The transaction is being conducted at arm's length, and the buyers are not related parties as defined under the Companies Act, 2013 or SEBI regulations.

Board Recommendation

The Board of Directors considers this transaction to be in the best interest of the company and its shareholders and recommends the resolution for approval as a Special Resolution.

Shareholders are advised to carefully review the postal ballot notice and cast their votes through the e-voting system provided by CDSL. The results of the postal ballot will be announced on or before October 14, 2025, and will be available on the company's website and stock exchange platforms.

Phaarmasia Limited , a pharmaceutical company, has reported its financial results for the first quarter ended June 30, 2025. The company has shown significant improvement in its performance compared to the previous quarter.

Key Financial Highlights

• Revenue from operations stood at Rs 687.36 lakhs, up 26.6% from Rs 542.99 lakhs in the previous quarter.
• Net profit for the quarter was Rs 27.02 lakhs, compared to a loss of Rs 52.50 lakhs in the previous quarter.
• Total income reached Rs 718.88 lakhs, while total expenses were Rs 687.58 lakhs.
• Earnings per share (EPS) for the quarter was Rs 0.40.

Quarterly Performance Analysis

Phaarmasia Limited has demonstrated a strong recovery in its first-quarter performance. The company's revenue from operations increased by 26.6% quarter-over-quarter, indicating improved business activity. However, it's worth noting that the revenue is still lower compared to the same quarter last year, which stood at Rs 829.19 lakhs.

The most significant improvement was seen in the company's bottom line. Phaarmasia Limited successfully turned around its financial performance, reporting a net profit of Rs 27.02 lakhs in Q1, compared to a loss of Rs 52.50 lakhs in the previous quarter. This represents a positive shift in the company's profitability.

Expense Management and Operational Efficiency

The company's total expenses for the quarter were Rs 687.58 lakhs, which is higher than the previous quarter but lower than the same quarter last year. This suggests that while business activity has increased, Phaarmasia Limited has managed to keep its expenses in check, contributing to the improved profitability.

Financial Position

Phaarmasia Limited maintained its paid-up equity share capital at Rs 682.70 lakhs. The company reported zero outstanding loans or debt securities, indicating a stable financial position.

Board Approval and Reporting Compliance

The Board of Directors approved these results at their meeting held on August 11, 2025. The company has submitted its integrated filing for the quarter ended June 30, 2025, in compliance with regulatory requirements.

Business Segment and Future Outlook

Phaarmasia Limited operates in a single business segment. While the company has shown improvement in its quarterly performance, it will be important to monitor how it sustains and builds upon this growth in the coming quarters, especially considering the year-on-year decline in revenue.

Investors and stakeholders will likely be watching closely to see if the company can maintain its profitability and potentially return to year-on-year growth in the subsequent quarters.